Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Completed · Phase 3

Conditions studied: Rheumatoid Arthritis

In brief

The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.

Key facts

Study ID

NCT03120949

Run by

R-Pharm International, LLC

People needed

2106

Starts

2017-07-04

Expected to finish

2021-09-01

Last updated by the study team

2023-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects may be enrolled in the study only if they meet all of the following criteria:
• Subject must be willing and able to sign informed consent
• Subject must have completed the 24-week double-blind Treatment Period in 1 of the 3 core studies (CL04041022, CL04041023, or CL04041025).
• Subject must have maintained their stable dose (and route) of MTX 15 to 25 mg/week (or ≥ 10 mg/week if there is documented intolerance to higher doses) during the core study and plan to maintain the same dose and route of administration for ≥ 12 additional weeks
• Subjects must be willing to take folic acid or equivalent throughout the study.

You may not qualify if…

• Subject with any medically important condition in the core study (e.g., clinically significant laboratory values, frequent Adverse events (AEs) or serious adverse events (SAEs), infection SAEs, and/or other concurrent severe and/or uncontrolled medical condition) which would make this subject unsuitable for inclusion in the open-label extension (OLE) study in the Investigator's judgement.
• Subject has evidence of active tuberculosis (TB)
• Subject with a positive or repeated indeterminate interferon-gamma release assay (IGRA) result at Week 22 of the core study
• Subjects may be enrolled in the OLE study if they fulfill all 3 of the following criteria prior to the first dose of study treatment:
• Active TB is ruled out by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice);
• The subject starts prophylaxis for latent TB infection (LTBI) according to country-specific/Centers for Disease Control and Prevention (CDC) guidelines (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for this study and it should not be used); and
• The subject is willing to complete the entire course of recommended LTBI therapy.
• Subject has planned surgery during the first 12 weeks of the OLE study
• Female subjects who are pregnant or who are planning to become pregnant during the study or within 6 months of the last dose of study drug
• Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol <20 pg/mL) who are not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.
• Highly effective contraception is defined as:
• Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of study treatment in the core study
• In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by documented follow-up hormone level assessment
• Total abstinence if it is the preferred and constant lifestyle of the subject. Thus, periodic abstinence such as ovulation, symptothermal, postovulation, calendar methods, and withdrawal are not acceptable methods of contraception.
• Male sterilization surgery: at least 6 months prior to the first dose of study treatment in the core study (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate). For female subjects, the vasectomized male should be the only partner.
• Placement of established intrauterine device (IUD): IUD copper or IUD with progesterone
• Barrier method (condom and intravaginal spermicide, cervical caps with spermicide, or diaphragm with spermicide) in combination with the following: established oral, injected, or implanted hormone methods of contraception or contraceptive patch.
• Subject is unwilling or unable to follow the procedures outlined in the protocol.
• Other medical or psychiatric conditions, or laboratory abnormalities that may increase the potential risk associated with study participation and administration of the study treatment, or that may affect study results interpretation and, as per Investigator's judgement, make the subject ineligible.

Where it is running

• Arizona Arthritis & Rheumatology Associates, P.C. — Phoenix, Arizona, United States
• Arizona Arthritis & Rheumatology Research, PLLC — Sun City, Arizona, United States
• CHI St. Vincent Hot Springs — Hot Springs, Arkansas, United States
• Medvin Clinical Research — Covina, California, United States
• C.V Mehta MD Med Corp.. — Hemet, California, United States
• Advanced Medical Research, LLC — La Palma, California, United States
• Valerius Medical Group — Los Alamitos, California, United States
• Stanford University School of Medicine — Palo Alto, California, United States
• Rheumatology Center of San Diego — San Diego, California, United States
• East Bay Rheumatology Medical Group, Inc. — San Leandro, California, United States
• Inland Rheumatology Clinical Trials, Inc. — Upland, California, United States
• Center for Rheumatology Research, Comprehensive Rheumatology Center — West Hills, California, United States
• Medvin Clinical Research — Whittier, California, United States
• Denver Arthritis Clinic — Denver, Colorado, United States
• New England Research Associates LLC — Bridgeport, Connecticut, United States
• Javed Rheumatology Associates — Newark, Delaware, United States
• RASF - Clinical Research Center — Boca Raton, Florida, United States
• Reliable Clinical Research, LLC — Hialeah, Florida, United States
• Pharmax Research Clinic — Miami, Florida, United States
• Medical Research Center of Miami — Miami, Florida, United States
• Suncoast Research Group, LLC — Miami, Florida, United States
• Omega Research Consultants — Orlando, Florida, United States
• Arthritis Research of Florida, INC — Palm Harbor, Florida, United States
• Family Clinical Trials, LLC. — Pembroke Pines, Florida, United States
• AZ Arthritis & Rheum' Research — Mesa, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.